Specificity of antinuclear and antiphospholipid antibodies in sera of patients with autoimmune lymphoproliferative disease (ALD)

Clinical and Experimental Rheumatology

Volumn 21, Issue 3, 2003, Pages 377-385

  Pittoni, V ^c   Sorice, M ^a   Circella, A ^a   Cangemi, R ^c   Conti, L ^a   Ramenghi, U ^b   Gandolfo, G M ^a   Dianzani, U ^b   Valesini, Guido ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

Author keywords

Antinuclear antibodies; Antiphospholipid antibodies; Apoptosis; Autoimmune lymphoproliferative syndrome; Fas

Indexed keywords

ANTINUCLEAR ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CELL NUCLEUS ANTIGEN; DOUBLE STRANDED DNA; FAS ANTIBODY; LIPOCORTIN 5; MEMBRANE ANTIGEN; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; PROTEIN S; PROTHROMBIN ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL CLONING; CELL MEMBRANE TRANSPORT; CELL NUCLEUS; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; LYMPHOPROLIFERATIVE DISEASE; MALE; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN TARGETING; STANDARDIZATION; T LYMPHOCYTE; THIN LAYER CHROMATOGRAPHY; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASES; BLOTTING, WESTERN; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; PROGNOSIS; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0037534362     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. CASCIOLA-ROSEN L, ROSEN A, PETRI M, SCHLISSEL M: Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implication for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 1996; 93: 1624-9.
2. PITTONI V, ISENBERG DA: Apoptosis and antiphospholipid antibodies.. Semin Arthritis Rheum 1998; 28: 163-78.
3. WILSON WA, GHARAVI AE, KOIKE T et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999; 42: 109-11.
4. NAGATA S, GODSTEIN P: The Fas death factor. Science 1993; 267: 1449-56.
5. LE DEIST F, EMILE JF, RIEUX-LAUCAT F et al.: Clinical immunological and pathological consequences of Fas-deficient conditions. Lancet 1996; 348: 719-23.
6. RIEUX-LUCAT F, LE DEIST F, HIVROZ C et al.: Mutation in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347-49.
7. WATANABE-FUKUNAGA R, BRANNAN CI, COPELAND NG, JENKIS NA, NAGATA S: Lymphoproliferation disorder in mice explained by defect in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-17.
8. DIANZANI U, BRAGARDO M, DI FRANCO D et al.: Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood 1997; 89: 2871-89.
9. STAUSS SE, SNELLER M, LENARDO MJ, PUCK JM, STOBER W: An inherited disorder of lymphocyte apoptosis: The autoimmune lymphoproliferative disorder. Ann Intern Med 1999; 130: 591-601.
10. PIGNATA C, ALESSIO M, RAMENCHI U et al.: Clustering of distinct autoimmune diseases associated with functional abnormalities of T cell survival in children. Clin Exp Immunol 2000; 121: 53-8.
11. SMITH CA, WILLIAMS GT, KINGSTON R, JENKINSON EJ, OWEN JT: Antibodies to CD3/T cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 1989; 337: 181-4.
12. OSMOND DG, RICO-VARGAS S, VALENZONA H, FAUTEUX L, JANARI R, JACOBSEN LK: Apoptosis and macrophage-mediated cell deletion in the regulation of B lymphopoiesis in mouse bone marrow. Immunol Rev 1994; 142: 209-30.
13. AKBAR AN, SALMON N: Cellular environment and apoptosis: Tissue microenvironments control activated T-cell death. Immunol Today 1997; 18: 72-76.
14. SORICE M, GRIGGI T, CIRCELLA A et al.: Detection of antiphospholipid antibodies by immunostaining on thin layer chromatography plates. J Immunol Methods 1994; 173: 49-54.
15. SORICE M, PITTONI V, GRIGGI T et al.: Specificity of antiphospholipid antibodies in infectious mononucleosis: A role for anti-cofactor protein antibodies. Clin Exp Immunol 2000; 120: 301-6.
16. KABURAKI J, KUWANA M, YAMAMOTO M, KAWAI S, IKEDA Y: Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 1997; 54: 209-13.
17. VAISHNAW AK, TOUBI E, OHSAKO S et al.: The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. Arthritis Rheum 1999; 42: 1833-42.
18. RAMENGHI U, BONISSONI S, MIGLIARETTI G et al.: Deficiency of Fas apoptosis pathway without Fas gene mutations is a familiar trait predisposing to development of autoimmune diseases and cancer. Blood 2000; 95: 3176-82.
19. COMI C, LEONE M, BONISSONI S et al.: Defective T cell fas function in patients with multiple sclerosis. Neurology 2000; 55: 921-27.
20. KANAI Y, KYUWA S, MIURA K, KUROSAWA Y: Induction and natural occurrence of serum nucleosomal DNA in autoimmune MRL/lpr/lpr mice: Its relationship to apoptosis in the thymus. Immunol Lett 1995; 46: 207-17.
21. EMLEN W, NIEBUR J, KADERA R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152: 3685-92.
22. CASCIOLA-ROSEN LA, ANHALT G, ROSEN A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317-30.
23. OVERZET K, GENSLER TJ, KIM SJ et al.: Small nucleolar RNP scleroderma autoantigens associate with phosphorylated serine/arginine splicing factors during apoptosis. Arthritis Rheum 2000; 43: 1327-36.
24. PELLICIARI C, BOTTONE MG, BIGGIOGERA M: Restructuring and extrusion of nuclear ribonucleoproteins (RNPs) during apoptosis. Gen Physiol Biophys 1999; 18: 50-2.
25. CABRESPINES A, LADERACH D, LEBOSSE C, BACH JF, KOUTOUZOF S: Isolation and characterization of apoptotic nucleosomes, free and complexed with lupus autoantibody generated during hybridoma B cell apoptosis. J Autoimmun 1998; 11: 19-27.
26. SORICE M, CIRCELLA A, GRIGGI T et al.: Anticardiolipin and anti-β2GP I are two distinct populations of autoantibodies. Thromb Haemost 1996: 75; 303-8.
27. FADOK V, VOELKER DR, CAMPBELL PA, COHEN JJ, BRATTON DL, HENSON PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148: 2207-16.
28. SORICE M, CIRCELLA A, MISASI R et al.: Cardiolipin on the surface of apoptotic cells as a possible trigger for antiphospholipid antibodies. Clin Exp Immunol 2000; 122: 277-84.
29. AMENGUAL O, ATSUMI T, KHAMASHTA MA, KOIKE T, HUGHES GRV: Specificity of ELISA for antibody to β2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996; 35: 1239-43.
30. ARVIEUX J, DARNIGE L, CARON C, REBER G, BENSA JC, COLOMB MG: Development of a ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 1120-25.
31. KABURAKI J, KUWANA M, YAMAMOTO M, KAWAI S, IKEDA Y: Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 1997; 54: 209-13.
32. PRICE BE, RAUCH J, SHIA MA et al.: Antiphospholipid antibodies bind to apoptotic but not viable thymocytes in a beta2-glycoprotein I-dependent manner. J Immunol 1996; 157: 2201-8.
33. PITTONI V, RAVIRAJAN, DONOHOE S, MACHIN SJ, LYDYARD PM, ISENBERG DA: Human monoclonal antiphospholipid antibodies selectively bind to membrane phospholipids and β2-Glycoprotein I on apoptotic cells. Clin Exp Immunol 2000; 119: 533-43.
34. CARTER LB, PROCTER JL, DALE JK, STRAUSS SE, CANTILENA CC: Description of serologic features of autoimmune lymphoproliferative syndrome. Transfusion 2000; 40: 943-8.